Equities

Smith & Nephew PLC

SN.:LSE

Smith & Nephew PLC

Health CareMedical Equipment and Services
  • Price (GBX)993.00
  • Today's Change7.40 / 0.75%
  • Shares traded-1.00
  • 1 Year change-22.33%
  • Beta0.8854
Data delayed at least 20 minutes, as of May 03 2024 08:40 BST.
More ▼

Forecasts data is unavailable for this security.

Consensus recommendation

  • 18-May-23
  • 15-Feb-24
  • 14-Mar-24
  • 18-Apr-24
  • 25-Apr-24
Select bar for recommendation details.
Recommendations25-Apr-24
Buy5
Outperform7
Hold5
Underperform1
Sell0

Share price forecast

The 17 analysts offering 12 month price targets for Smith & Nephew plc have a median target of 1,298.87, with a high estimate of 1,499.12 and a low estimate of 1,073.88. The median estimate represents a 31.78% increase from the last price of 985.60.
High52.1%1,499.12
Med31.8%1,298.87
Low9.0%1,073.88

Dividends

In 2023, Smith & Nephew PLC reported a dividend of 0.23 USD, which represents a 38.97% decrease from last year. The 18 analysts covering the company expect dividends of 0.38 USD for the upcoming fiscal year, an increase of 65.80%.
Div growth (TTM)-38.97%
More ▼

Earnings history & estimates

Smith & Nephew plc reported annual 2023 earnings of 0.828 per share on Feb 27, 2024.
Average growth rate-2.36%
More ▼

Revenue history & estimates

Smith & Nephew plc had 1st quarter 2024 revenues of 1.39bn. This missed the 1.40bn consensus estimate of the 6 analysts following the company. This was 2.21% above the prior year's 1st quarter results.
Average growth rate+0.65%
Smith & Nephew plc had revenues for the full year 2023 of 5.55bn. This was 6.40% above the prior year's results.
Average growth rate+2.38%
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.